NYKODE THERAPEUTICS Oslo, Norway ,May 05, 2021 -Vaccibody AS , a clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies, today announced the appointment ofDr. Volck , M.D., Ph.D. to its Board of Directors. "I am excited to welcome Dr.Birgitte Volck to our Board.Dr. Volck is a seasoned R&D executive with broad international experience. Her valuable expertise will help guide and supportVaccibody in this transformational period of expansion and clinical pipeline acceleration." saidAnders Tuv , Chairperson ofVaccibody AS .Dr. Volck has over 20 years of leadership experience in the biotechnology and pharmaceutical industry.Dr. Volck has served as the President R&D atAVROBIO Inc. (Nasdaq), a clinical stage gene therapy company. Prior to this, she served as head of Research and Development, Rare Diseases, forGlaxoSmithKline . Before that,Dr. Volck was the Chief Medical Officer and Senior Vice President of Development atSwedish Orphan Biovitrum AB . She has held various positions atAmgen Inc. , includingExecutive Development Director, Bone, Neuroscience & Inflammation and served as Nordic Medical Director andProject Director at Genzyme A/S. She currently serves as Director ofAscendis Pharma A/S (Nasdaq) andSoleno Therapeutics Inc. (Nasdaq).Dr. Volck received her M.D. and Ph.D. degrees fromCopenhagen University ,Denmark . AboutVaccibody Vaccibody AS , is a clinical-stage biopharmaceutical company, dedicated to the discovery and development of vaccines and novel immunotherapies. The Company develops vaccines for the treatment cancer and infectious diseases.Vaccibody's vaccine technology specifically targets antigens to Antigen Presenting Cells, which are essential for inducing rapid, strong and long-lasting antigen-specific immune responses and elicit efficacious clinical responses. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is exclusively outlicensed toGenentech and is in phase I/IIa clinical trial for the treatment of melanoma, lung-, head and neck, renal-, and bladder cancer; and VB10.16, a therapeutic vaccine for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer and cancer of the head & neck. Further, the Company has collaborations withRoche andNektar Therapeutics within oncology. Additionally,Vaccibody intends to leverage the potential of its platform in infectious disease indications, including its second-generation COVID-19 vaccine program, VB10.COV2.Vaccibody's shares are traded on Euronext Growth (Oslo ), a trading platform operated by Euronext, the leading Pan-European market infrastructure. The ticker code is VACC. Further information aboutVaccibody may be found at http://www.vaccibody.com Contact forVaccibody : CEOMichael Engsig Vaccibody AS Cell: +45 6173 1509 mengsig@vaccibody.comVaccibody AS Oslo Science Park Gaustadalléen 21 0349Oslo, Norway Forward-looking statements forVaccibody This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.
Click here for more information
© Oslo Bors ASA, source
